Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 May;136(5):639-50.
doi: 10.1007/s00432-010-0792-0. Epub 2010 Feb 6.

Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved

Alyse Hopkins  1 , Philip J Crowe, Jia-Lin Yang
Affiliations
Review

Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved

Alyse Hopkins et al. J Cancer Res Clin Oncol. 2010 May.

Abstract

Introduction: Chemotherapy is administered only to patients with advanced cancers, typically to modest avail. Hence, the search for innovative approaches to treat cancer is growing rapidly. One such approach involves targeting molecular pathways identified as encouraging tumor growth and maintenance, particularly the type 1 insulin-like growth factor (IGF-1) and its receptor (IGF-1R) pathway that is important in conferring chemoresistance.

Materials and methods: This study focuses on IGF-1R targeted therapy, which will enhance chemotherapy efficacy, through reviewing recent literature from PubMed and Medline databases.

Conclusion: This review examines data and strategies addressing an approach conquering chemoresistance through the combination of IGF-1R targeted therapy and chemotherapy in cancer patients, as well as the mechanisms by which IGF-1R acts as a target. This will impact on future research on treatment selection, thereby improving patient prognosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Mechanisms of action for chemotherapeutic drugs. Illustrates how each class of chemotherapeutic drugs interact with cell function. The lines indicate which section of the cell process each chemotherapeutic is having its effect
Fig. 2
Fig. 2
The interplay between p53, MDM2 and IGF-1R. MDM2 can decrease p53 synthesis, but also associate to it causing upregulation of p53. p19 ARF association to MDM2 prevents association to p53. The path taken when chemoresistant p53 mutant is present, is shown in thickened (red) arrows where IGF-1R is upregulated
Fig. 3
Fig. 3
Overview of major IGF-1R signaling pathways. Following ligand binding, the two major pathways are activated. The first is the Ras-Raf-MAPK pathway, which is involved in proliferation and differentiation of cells. The second is the PI3K-AKT-mTOR pathway, which is also involved in proliferation and cell growth, but also implicated in cell survival signals to inhibit anti-apoptotic proteins
Fig. 4
Fig. 4
IGF-1R pathways leading to development and maintenance of tumor cells. BAD deactivation induces anti-apoptotic protein expression, while the PI3K, MAPK and the 14-3-3 pathways all contribute to sustaining and repairing the cell through cell survival signals
See this image and copyright information in PMC

References

    1. Angelini A, Iezzi M, Di Febbo C, Di Ilio C, Cuccurullo F, Porreca E (2008) Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs. Oncol Rep 20:731–735 - PubMed
    1. Arora A, Scholar EM (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Therapeutics 315:971–979 - PubMed
    1. Atzori F, Tabernero J, Cervantes A, Botero M, Hsu K, Brown H et al (2008) A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors. ASCO Meet Abstr 26:3519
    1. Bohula EA, Playford MP, Macaulay VM (2003) Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment. Anticancer Drugs 14:669–682 - PubMed
    1. Burfeind P, Chernicky C, Rininsland F, Ilan J, Ilan J (1996) Antisense RNA to the type 1 insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 93:7263–7268 - PMC - PubMed

MeSH terms

LinkOut - more resources